文献速递骨软组织肉瘤与黑色素瘤

SAKK57/16 白蛋白结合型紫杉醇联合吉西他滨治疗软组织肉瘤(NAPAGE):一项 I/II 期试验

SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
PubMed 文献 · Eur J Cancer · 2023-12-09

NAPAGE 是一项 Ib/II 期临床试验,评估白蛋白结合型紫杉醇(nab-pc)联合吉西他滨在经治软组织肉瘤(STS)患者中的疗效与安全性,采用剂量递减队列和扩展队列。I 期给予 nab-pc 150 mg/m2 联合吉西他滨 1000 mg/m2 每两周一次,未出现剂量限制性毒性(DLT)或因不良事件(AE)停药,该剂量被推荐为 II 期推荐剂量(RP2D)。II 期主要终点 3 个月无进展率(PFR)为 56.4%(95%CI:39.6-72.2%),中位无进展生存期(PFS)5.3 个月(95%CI:1.4-8.2),中位总生存期(OS)12.8 个月(95%CI:10.5-39.2);结论认为联合方案安全,在经治 STS 患者中观察到有前景的抗肿瘤活性且毒性可控,该方案应被考虑进一步探索。

要点

  • I 期 nab-pc 150 mg/m2 联合吉西他滨 1000 mg/m2 每两周一次,未出现 DLT 或 AE 相关停药,确定为 RP2D。
  • II 期 3 个月 PFR 为 56.4%(95%CI:39.6-72.2%),中位 PFS 5.3 个月(95%CI:1.4-8.2),中位 OS 12.8 个月(95%CI:10.5-39.2)。
  • 最常见治疗相关 ≥3 级 AE 为中性粒细胞减少(18%),无 3-4 级周围感觉神经病变(PNP)报告。

核心结论

  • 白蛋白结合型紫杉醇联合吉西他滨方案安全,在经治软组织肉瘤患者中观察到有前景的活性且毒性可控,该方案应被考虑进一步探索。

研究设计与样本

  • NAPAGE 为 Ib/II 期临床试验,采用剂量递减队列和扩展队列两个队列。
  • I 期给予 nab-pc 150 mg/m2 联合吉西他滨 1000 mg/m2 每两周一次,直至疾病进展或不可接受的毒性。
  • 因未出现剂量限制性毒性(DLT)或因不良事件(AE)停药,该剂量被推荐为 II 期推荐剂量(RP2D)。
  • II 期主要终点为 3 个月无进展率(PFR)(H0:20%,H1:40%),次要终点包括 PFS、OS、AE、客观缓解和患者报告结局(PRO),疗效分析按意向治疗进行。

主要发现

  • 3 个月 PFR 为 56.4%(95%CI:39.6-72.2%)。
  • 3 个月和 6 个月 PFS 分别为 58.4%(95%CI:41.3-72.1%)和 44.6%(95%CI:28.4-59.5%)。
  • 中位 PFS 为 5.3 个月(95%CI:1.4-8.2),中位 OS 为 12.8 个月(95%CI:10.5-39.2)。
  • 最常见治疗相关 ≥3 级 AE 为中性粒细胞减少(18%),其次为贫血(2.6%)、高血压(2.6%)和丙氨酸氨基转移酶升高(2.6%)。
  • 1 级和 2 级周围感觉神经病变(PNP)分别发生于 15.4% 和 20.5% 的患者,未报告 3-4 级 PNP。

关键数值与推荐

  • I 期 nab-pc 150 mg/m2 联合吉西他滨 1000 mg/m2 每两周一次,未出现 DLT 或 AE 相关停药,确定为 RP2D。
  • II 期主要终点 3 个月 PFR 为 56.4%(95%CI:39.6-72.2%),无效假设 H0 为 20%,备择假设 H1 为 40%。

临床怎么用

  • 作者认为该联合方案安全,在经治软组织肉瘤患者中观察到有前景的活性且毒性可控,应被考虑进一步探索。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To determine whether the combination of nab-paclitaxel with gemcitabine has activity in patients with pretreated soft tissue sarcoma (STS). PATIENTS AND METHODS: NAPAGE is a phase Ib/II clinical trial investigating the combination of nab-paclitaxel (nab-pc) with gemcitabine employing two cohorts. One of a dose-de-escalation phase and one of expansion. In phase I, nab-pc was given at 150 mg/m2 in combination with gemcitabine 1000 mg/m2 every two weeks, until disease progression or unacceptable toxicity. This dose was recommended for phase II (RP2D), as there was no dose limiting toxicity (DLT) or discontinuations due to adverse events (AEs). The primary endpoint of the phase II was progression-free rate (PFR) at 3 months (H0: 20%, H1:40%). The secondary endpoints included progression free survival (PFS), overall survival (OS), AEs, objective response and patient-reported outcomes (PRO). Efficacy analysis was by intention to treat. RESULTS: The 3-month PFR was 56.4% (95% confidence interval CI: 39.6-72.2%). The 3-month and 6-month PFS were 58.4% (95% CI: 41.3-72.1%) and 44.6% (95% CI: 28.4-59.5%), respectively. Median PFS was 5.3 months (95% CI: 1.4-8.2) and median OS was 12.8 months (95% CI: 10.5-39.2). The most common treatment-related grade ≥ 3 AE were neutropenia (18%), followed by anemia (2.6%), hypertension (2.6%) and alanine aminotransferase increase (2.6%). Grade 1 and grade 2 peripheral sensory neuropathy (PNP) occurred in 15.4% and 20.5%, respectively. No grade 3-4 PNP was reported. CONCLUSIONS: Combining nab-pc and gemcitabine is safe. Promising activity is observed in pretreated STS patients with manageable toxicity. This regimen should be considered for further exploration.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Digklia A, Kollár A, Dietrich D, et al. SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial. Eur J Cancer. 2023. PMID: 38096656. doi:10.1016/j.ejca.2023.113470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。